top of page

 

 

Oxymetholone

 

 

 

 

​

​

​

​

​

​

​

​

Oxymetholone, sold under the brand names Anadrol and Anapolon, is an androgen and anabolic steroid (AAS) with various medical and non-medical uses. Here are the benefits, applications, and considerations associated with oxymetholone:

Medical Uses:

  1. Treatment of Anemia: Oxymetholone is primarily used to treat anemia, a condition characterized by a deficiency of red blood cells. It helps stimulate red blood cell production and can be beneficial in certain cases.

  2. Muscle Growth: The drug is known for its ability to promote muscle growth, making it useful in treating malnourished or underdeveloped patients.

  3. Osteoporosis Treatment: Oxymetholone has been used in the treatment of osteoporosis, a condition where bones become weak and brittle.

  4. HIV/AIDS Wasting Syndrome: It is employed to combat the muscle wasting associated with HIV/AIDS.

  5. Weight Gain: Oxymetholone is used to promote weight gain in specific situations, contributing to increased body mass.

Non-Medical Uses:

  1. Physique Enhancement: Athletes, bodybuilders, and powerlifters use oxymetholone for enhancing physique and performance.

  2. Anabolic Effects: Oxymetholone has strong anabolic effects, leading to extensive gains in body mass. This is particularly valuable for bodybuilders and athletes aiming for muscle development.

  3. Protein Synthesis Improvement: The drug significantly improves protein synthesis, aiding in muscle growth and recovery.

Side Effects and Considerations:

  1. Androgenic Effects: While oxymetholone has strong anabolic effects, its androgenic effects are relatively weak, reducing the risk of masculinization symptoms.

  2. Estrogenic Effects: Despite being a derivative of dihydrotestosterone (DHT), oxymetholone is associated with relatively high estrogenicity. This can lead to side effects like gynecomastia and water retention.

  3. Hepatotoxicity: Due to its 17α-alkylated structure, oxymetholone can cause liver damage. Long-term use may lead to serious ailments such as hepatitis, liver cancer, and cirrhosis.

  4. Other Side Effects: Common side effects include depression, lethargy, headache, swelling, rapid weight gain, priapism, changes in skin color, urination problems, nausea, vomiting, stomach pain, loss of appetite, jaundice, and more.

Pharmacology:

  1. Androgen Receptor Agonist: Oxymetholone acts as an agonist of the androgen receptor, showing a high ratio of anabolic to androgenic activity.

  2. Metabolism: Metabolized in the liver, oxymetholone is eliminated in the urine. Limited information is available on its pharmacokinetics.

Legal Status:

  1. Controlled Substance: Oxymetholone is classified as a Schedule III controlled substance in the United States under the Controlled Substances Act.

Availability:

  1. Medical Use in the U.S.: Oxymetholone remains available for medical use in the United States, prescribed for specific conditions.

​

References

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-15.

  2. ^ Jump up to:a b c d e Saartok T, Dahlberg E, Gustafsson JA (June 1984). "Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin". Endocrinology. 114 (6): 2100–6. doi:10.1210/endo-114-6-2100. PMID 6539197.

  3. ^ Jump up to:a b c d e f Hochadel M (1 April 2015). Mosby's Drug Reference for Health Professions. Elsevier Health Sciences. pp. 1221–. ISBN 978-0-323-31103-8.

  4. ^ Jump up to:a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah William Llewellyn (2011). Anabolics. Molecular Nutrition Llc. pp. 323–334. ISBN 978-0-9828280-1-4.

  5. ^ Jump up to:a b c d e f Pavlatos AM, Fultz O, Monberg MJ, Vootkur A (June 2001). "Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid". Clinical Therapeutics. 23 (6): 789–801, discussion 771. doi:10.1016/s0149-2918(01)80070-9. PMID 11440282.

  6. ^ "Oxymetholone Powder Uses". aea.ltd. Retrieved 2022-12-17.

  7. ^ Kicman AT (June 2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology. 154 (3): 502–21. doi:10.1038/bjp.2008.165. PMC 2439524. PMID 18500378.

  8. ^ Jump up to:a b Zderic JA, Carpio H, Ringold HJ (January 1959). "Steroids. CVI. Synthesis of 7β-Methyl Hormone Analogs". Journal of the American Chemical Society. 81 (2): 432–436. doi:10.1021/ja01511a041.

  9. ^ Jump up to:a b "Advertisements". Proceedings of the Royal Society of Medicine. 54 (3): XLI. 1961. PMC 1870224.

  10. ^ Jump up to:a b "Advertisements" (PDF). British Medical Journal. 1 (5224). 1961. PMC 1953122.

  11. ^ Jump up to:a b c d "Oxymetholone".

  12. ^ "Oxymetholone". AdisInsight. Springer Nature Switzerland AG.

  13. ^ "Anadrol-50" (PDF). Meda Pharmaceuticals. December 2006. Archived from the original (PDF) on 11 June 2014. Retrieved 8 January 2012.

  14. ^ Jump up to:a b c "Oxymetholone Side Effects". drugs.com.

  15. ^ Jump up to:a b "Anadrol Official FDA Information, Side Effects and Uses". drugs.com.

  16. ^ Hengge UR, Stocks K, Wiehler H, Faulkner S, Esser S, Lorenz C, et al. (March 2003). "Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting". AIDS. 17 (5): 699–710. doi:10.1097/00002030-200303280-00008. PMID 12646793. S2CID 29998317.

  17. ^ Cortesgallegos V, Castaneda G, Alonso R, Perezpasten E, Reyeslugo V, Barron C, Mondragon L, Villalpando S (January 1982). "Spontaneous and Oxymetholone-Induced Gynecomastia". Journal of Andrology. C/O Allen Press, Inc Po Box 368, Lawrence, Ks 66044: Amer Soc Andrology, Inc. 3 (1): 33.

  18. ^ Villalpando S, Mondragon L, Barron C, Reyeslugo U, Perezpasten E, Alonso R, Castaneda G, Gallegos V (January 1982). "5-Alpha Reductase Blockade May Be Responsible for Spontaneous and Oxymetholone-Induced Gynecomastia". Archivos de Investigacion Medica. Social Apdo Postal 73-032, Mexico Df 03020, Mexico: Inst Mexicano Seguro. 13 (2): s13.

  19. ^ Jump up to:a b c Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 924–. ISBN 978-1-4757-2085-3.

  20. ^ Jump up to:a b c d Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 779–. ISBN 978-3-88763-075-1.

  21. ^ Locum R (1961). "Latest Pharmaceutical Preparations" (PDF). The Central African Journal of Medicine. 7 (11): 443–444.

  22. ^ Clark GM (August 1962). "New drugs in rheumatic disease". Arthritis and Rheumatism. 5 (4): 415–8. doi:10.1002/art.1780050411. PMID 13879693.

  23. ^ Matusow PD (1962). "If - Then; C.A.M.S.I.; In the future" (PDF). Dalhousie Medical Journal. 15 (1).

  24. ^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 212–. ISBN 978-94-011-4439-1.

  25. ^ Kochakian CD (6 December 2012). Anabolic-Androgenic Steroids. Springer Science & Business Media. pp. 632–. ISBN 978-3-642-66353-6.

  26. ^ Jump up to:a b "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 17 December 2016.

  27. ^ Karch SB (21 December 2006). Drug Abuse Handbook, Second Edition. CRC Press. pp. 30–. ISBN 978-1-4200-0346-8.

​

oxymethalone_edited.png
bottom of page